EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Lakefront Biotherapeutics NV (0JXZ) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Lakefront Biotherapeutics NV €7.61, price €26.01, upside -70.7%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · GB · ISIN BE0003818359

LB Thin data Sep 24, 2026

Lakefront Biotherapeutics NV

0JXZ · LSE

Weakest SetupStrongly overvalued and low quality.

!Fair value €7.61 · Strongly overvalued (−70.7%)
!Quality 31/100
!Mixed Growth (revenue 3y +50.4 %/yr)
✓Highly profitable · 46.8% net margin (TTM)
!Moderate moat 60/100
!Evidence only low, so the estimate is less certain
Watch Lakefront Biotherapeutics NV for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€65.53 €21.10 Fair Value €7.61 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range €21.10 – €65.53 · fair‑value band €5.02 – €9.51 · the €26.01 price screens above the €7.61 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

Show more

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Stock analysis

Lakefront Biotherapeutics NV (0JXZ) currently trades at €26.01, while our model-based Fair Value estimate is €7.61, 70.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: €5.02 (bear) to €9.51 (bull), the price of €26.01 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Lakefront Biotherapeutics NV reported revenue of €530M in FY2020 versus €152M in FY2016, a compound +36.8%/yr. Reported net income was −€305M in FY2020.

Key figures

Market cap €3.9B · P/S ratio 3.71 · Net margin −57.6% · Return on equity 16.3% · Return on assets (EBIT) −1.6% · Operating margin −983% · Revenue (TTM) €1.0B · Revenue growth (YoY) −91.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 19% below its 52-week high and 15% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −71%, 0JXZ screens richer than that median.

Fair Value models

Bear €5.02 Fair Value €7.61 Bull €9.51
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) €8.97 €12.02 €17.94 51
All 1 models by family
Asset-Based
NCAV (Graham) €8.97 €12.02 €17.94 51

Open the full fair value analysis →

Notify me when 0JXZ reaches fair value

Put 0JXZ on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 31/100

Of which business quality 31 · Market factors (momentum, volatility) 45

Profitability 0
Margins and returns on capital today
Quality Growth 8
Are margins and returns improving?
Cashflow 59
Earnings quality: real cash, not paper profit
Fin. Strength 49
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 81
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 25
Distance to the 52-week high (market factor)

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−40.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7.6% (2016) → −33.7% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
not computed

0JXZ screens overvalued: fair value 71% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Lakefront Biotherapeutics NV with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 629 stocks

Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −68.8% · Below median
Profitability
Return on equity (TTM) 16.3% · Top 25%
Return on assets 10.7% · Top 25%
Net margin (TTM) 46.8% · Top 25%
Growth and dividend
Revenue growth −91.4% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.68× · Cheaper than median
P/S (TTM) 4.31× · Cheaper than median
EV/EBITDA 6.5× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lakefront Biotherapeutics NV · Fair Value
€7.61 −71%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lakefront Biotherapeutics NV Fair Value". https://www.fairvalue-calculator.com/stock/0JXZ

Frequently asked questions

Is Lakefront Biotherapeutics NV (0JXZ) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €7.61 versus a price of €26.01, about −71% upside (overvalued).
What is the fair value of 0JXZ?
Our model-based fair value for Lakefront Biotherapeutics NV is €7.61 (as of Sep 24, 2026), built from audited fundamentals. The current price: €26.01.
What is the quality score of 0JXZ?
Lakefront Biotherapeutics NV has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lakefront Biotherapeutics NV (0JXZ)?
Our model-based price target is the fair value of €7.61 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario €5.02, optimistic scenario €9.51. It is a calculation from audited fundamentals, not an analyst target.
What is the Lakefront Biotherapeutics NV stock forecast for 2026?
Our models put fair value at €7.61, about −71% upside versus a price of €26.01 (overvalued). Cautious scenario €5.02, optimistic scenario €9.51. The calculation is refreshed regularly with new filings.
What is the revenue of Lakefront Biotherapeutics NV (0JXZ)?
Lakefront Biotherapeutics NV reported trailing-twelve-month revenue of about €1.0B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Lakefront Biotherapeutics NV (0JXZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lakefront Biotherapeutics NV it is €7.61 per share (as of Sep 24, 2026), against a price of €26.01. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Lakefront Biotherapeutics NV stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0JXZ trades above its calculated fair value: price €26.01, fair value €7.61, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0JXZ?
No. The price is what the market pays today (€26.01); the fair value is what the company's own numbers justify (€7.61). For Lakefront Biotherapeutics NV the two are €18.40 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lakefront Biotherapeutics NV worth?
The market values Lakefront Biotherapeutics NV at about €3.9B (market capitalisation, as of Sep 24, 2026). Per share that is €26.01; our models calculate a fair value of €7.61 per share.
What do the bullish and bearish scenarios say about 0JXZ?
Our models span a range for Lakefront Biotherapeutics NV: cautious scenario €5.02, base €7.61, optimistic €9.51 per share (as of Sep 24, 2026, price €26.01). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lakefront Biotherapeutics NV (0JXZ)?
Balance-sheet figures for Lakefront Biotherapeutics NV (as of Sep 24, 2026): return on equity 16.3%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 0JXZ from its 52-week high?
Lakefront Biotherapeutics NV trades at €26.01, about 19% below its 52-week high of €31.93 and 15% above the low of €22.54 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €7.61 is for.
Which stocks are comparable to Lakefront Biotherapeutics NV?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lakefront Biotherapeutics NV stock attractive at the current price?
The data as of Sep 24, 2026: price €26.01, calculated fair value €7.61 (−71%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0JXZ calculated?
We run Lakefront Biotherapeutics NV through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €7.61, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Lakefront Biotherapeutics NV itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lakefront Biotherapeutics NV (0JXZ)?
The closing price on Oct 2, 2026 was €26.01. Our model-based fair value is €7.61, about −71% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lakefront Biotherapeutics NV right now?
The price sits above even our optimistic bull case (€9.51). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€5.02 to €9.51) leaves room in how you read the outcome.

Key figures of Lakefront Biotherapeutics NV

How large is the market capitalisation of Lakefront Biotherapeutics NV (0JXZ)?
The market capitalisation of Lakefront Biotherapeutics NV is €3.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lakefront Biotherapeutics NV (0JXZ)?
The price-to-sales ratio of Lakefront Biotherapeutics NV is 3.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Lakefront Biotherapeutics NV (0JXZ)?
The net margin of Lakefront Biotherapeutics NV is −57.6% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lakefront Biotherapeutics NV (0JXZ)?
The return on equity (ROE) of Lakefront Biotherapeutics NV is 16.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lakefront Biotherapeutics NV (0JXZ)?
On an EBIT basis the return on assets of Lakefront Biotherapeutics NV is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lakefront Biotherapeutics NV (0JXZ)?
The operating margin of Lakefront Biotherapeutics NV is −983% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lakefront Biotherapeutics NV (0JXZ)?
Revenue at Lakefront Biotherapeutics NV is growing −91.4% versus a year earlier (3y avg +50.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lakefront Biotherapeutics NV (0JXZ)?
Earnings per share at Lakefront Biotherapeutics NV are growing +30.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Lakefront Biotherapeutics NV in the live analysis

One click puts Lakefront Biotherapeutics NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.